Cartesian Therapeutics (RNAC) Shares Outstanding (2015 - 2026)
Cartesian Therapeutics (RNAC) posted quarterly Shares Outstanding (Entity) of $28.5 million for Q1 2026, up 10.06% year-over-year from $25.9 million in Q1 2025, and up 9.74% quarter-over-quarter from $26.0 million in Q4 2025.
Cartesian Therapeutics (RNAC) Shares Outstanding (2015 - 2026) Analysis & Trends
Cartesian Therapeutics (RNAC) has reported Shares Outstanding (Entity) for 12 consecutive years, with $28.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 10.06% year-over-year to $28.5 million; the TTM figure through Mar 2026 stood at $28.5 million (up 10.06% YoY), while the FY2025 annual figure was $26.0 million, up 50.55% from the prior year.
- Shares Outstanding (Entity) advanced to $28.5 million in Q1 2026 per RNAC's latest filing, from $26.0 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $28.5 million in Q1 2026 and bottomed at $4.1 million in Q1 2022.
- Historically, Shares Outstanding (Entity) has averaged $14.0 million across 5 years, with a median of $5.5 million in 2024.
- Annual changes were most pronounced in 2023 — Shares Outstanding (Entity) climbed 0.47% — and 2025, when it surged 370.21%.
- Cartesian Therapeutics' Shares Outstanding (Entity) stood at $5.1 million in 2022, then grew by 5.82% to $5.4 million in 2023, then surged by 220.08% to $17.3 million in 2024, then jumped by 50.55% to $26.0 million in 2025, then increased by 9.74% to $28.5 million in 2026.
- Business Quant data shows RNAC's Shares Outstanding (Entity) at $28.5 million in Q1 2026, $26.0 million in Q4 2025, and $26.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Cartesian Therapeutics | 265.54 Mn | 265.54 Mn | - | 29.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 29.47 Mn |
| Mar 31, 2026 | 26.86 Mn |
| Dec 31, 2025 | 25.97 Mn |
| Sep 30, 2025 | 26.00 Mn |
| Jun 30, 2025 | 25.98 Mn |
| Mar 31, 2025 | 25.90 Mn |
| Dec 31, 2024 | 17.28 Mn |
| Sep 30, 2024 | 21.47 Mn |
| Jun 30, 2024 | 16.72 Mn |
| Mar 31, 2024 | 5.41 Mn |
| Dec 31, 2023 | 5.17 Mn |
| Sep 30, 2023 | 5.16 Mn |
| Jun 30, 2023 | 5.11 Mn |
| Mar 31, 2023 | 5.11 Mn |
| Dec 31, 2022 | 4.82 Mn |
| Sep 30, 2022 | 5.09 Mn |
| Jun 30, 2022 | 4.95 Mn |
| Mar 31, 2022 | 4.14 Mn |
| Dec 31, 2021 | 3.81 Mn |
| Sep 30, 2021 | 3.84 Mn |